Тип публикации: статья из журнала
Год издания: 2021
Идентификатор DOI: 10.1134/S1990519X2103007X
Ключевые слова: cell cycle, G<inf>0</inf>, ki-67, melanoma, Quiescent cells, Vemurafenib
Аннотация: Vemurafenib revolutionized the treatment of melanomas which harbor mutations in BRAF oncogene whereas BRAF-negative tumors are resistant to its antitumor effects. Meanwhile tumor chemoresistance is associated with the presence of quiescent, resting-dormant (G0-positive, Ki-67-negative) cancer cells in the heterogeneous cancer cell population. In order to test if BRAF-inhibitor can stimulate quiescence in melanoma cells, two melanoma cell lines (BRO and SK-MEL-2) were treated with the antitumor drug vemurafenib, and populations with G1/G0 cell cycle arrest were obtained. The latter were confirmed by negative staining with Ki-67 antibodies, and changes in the gene expression of cell cycle regulatory proteins, such as CDK4, CCND1 and CDKN1B.
Журнал: Cell and Tissue Biology
Выпуск журнала: Т. 15, № 3
Номера страниц: 227-235
ISSN журнала: 1990519X
Место издания: Санкт-Петербург
Издатель: Pleiades Publishing, Ltd. (Плеадес Паблишинг, Лтд)